310 related articles for article (PubMed ID: 28965082)
1. Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity.
Zheng X; Ma W; Sun R; Yin H; Lin F; Liu Y; Xu W; Zeng H
Redox Biol; 2018 Apr; 14():237-249. PubMed ID: 28965082
[TBL] [Abstract][Full Text] [Related]
2. The antimetastatic effect and underlying mechanisms of thioredoxin reductase inhibitor ethaselen.
Zheng X; Chen Y; Bai M; Liu Y; Xu B; Sun R; Zeng H
Free Radic Biol Med; 2019 Feb; 131():7-17. PubMed ID: 30496814
[TBL] [Abstract][Full Text] [Related]
3. Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression.
Zou Q; Chen YF; Zheng XQ; Ye SF; Xu BY; Liu YX; Zeng HH
J Zhejiang Univ Sci B; 2018 Sept.; 19(9):689-698. PubMed ID: 30178635
[TBL] [Abstract][Full Text] [Related]
4. Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells.
Chen X; Zhu N; Wu Y; Zhang Y; Zhang Y; Jin K; Zhou Z; Chen G; Wang J
Phytomedicine; 2024 Jun; 128():155317. PubMed ID: 38537439
[TBL] [Abstract][Full Text] [Related]
5. [Correlation of plasma thioredoxin reductase activity to growth of H22 hepatocellular carcinoma xenografts in Kunming mice].
Tan Q; Ren XY; Li J; Wang F; Deng SJ; Zeng HH
Ai Zheng; 2009 May; 28(5):472-7. PubMed ID: 19624873
[TBL] [Abstract][Full Text] [Related]
6. Carnosic acid induces apoptosis of hepatocellular carcinoma cells via ROS-mediated mitochondrial pathway.
Zhang X; Chen Y; Cai G; Li X; Wang D
Chem Biol Interact; 2017 Nov; 277():91-100. PubMed ID: 28918123
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of gold(III) Schiff base complexes for the treatment of hepatocellular carcinoma through attenuating TrxR activity.
Bian M; Wang X; Sun Y; Liu W
Eur J Med Chem; 2020 May; 193():112234. PubMed ID: 32213395
[TBL] [Abstract][Full Text] [Related]
8. Activation of reactive oxygen species-mediated mitogen-activated protein kinases pathway regulates both extrinsic and intrinsic apoptosis induced by arctigenin in Hep G2.
Lu Z; Zhou H; Zhang S; Dai W; Zhang Y; Hong L; Chen F; Cao J
J Pharm Pharmacol; 2020 Jan; 72(1):29-43. PubMed ID: 31617221
[TBL] [Abstract][Full Text] [Related]
9. Pentoxifylline induces apoptosis of HepG2 cells by reducing reactive oxygen species production and activating the MAPK signaling.
Wang Y; Dong L; Li J; Luo M; Shang B
Life Sci; 2017 Aug; 183():60-68. PubMed ID: 28583366
[TBL] [Abstract][Full Text] [Related]
10. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis oxidative damage-mediated and antiproliferative effect of selenylated imidazo[1,2-a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo.
Dos Santos DC; Rafique J; Saba S; Almeida GM; Siminski T; Pádua C; Filho DW; Zamoner A; Braga AL; Pedrosa RC; Ourique F
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22663. PubMed ID: 33125183
[TBL] [Abstract][Full Text] [Related]
12. Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma.
Lee D; Xu IM; Chiu DK; Leibold J; Tse AP; Bao MH; Yuen VW; Chan CY; Lai RK; Chin DW; Chan DF; Cheung TT; Chok SH; Wong CM; Lowe SW; Ng IO; Wong CC
Hepatology; 2019 Apr; 69(4):1768-1786. PubMed ID: 30561826
[TBL] [Abstract][Full Text] [Related]
13. Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells.
Zheng X; Xu W; Sun R; Yin H; Dong C; Zeng H
Chem Biol Interact; 2017 Sep; 275():74-85. PubMed ID: 28757135
[TBL] [Abstract][Full Text] [Related]
14. The role of thioredoxin reductase and glutathione reductase in plumbagin-induced, reactive oxygen species-mediated apoptosis in cancer cell lines.
Hwang GH; Ryu JM; Jeon YJ; Choi J; Han HJ; Lee YM; Lee S; Bae JS; Jung JW; Chang W; Kim LK; Jee JG; Lee MY
Eur J Pharmacol; 2015 Oct; 765():384-93. PubMed ID: 26341012
[TBL] [Abstract][Full Text] [Related]
15. Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux.
Chen C; Ai QD; Wei YH
J Ethnopharmacol; 2021 Jan; 264():113388. PubMed ID: 32918990
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
Coriat R; Nicco C; Chéreau C; Mir O; Alexandre J; Ropert S; Weill B; Chaussade S; Goldwasser F; Batteux F
Mol Cancer Ther; 2012 Oct; 11(10):2284-93. PubMed ID: 22902857
[TBL] [Abstract][Full Text] [Related]
17. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
Oncotarget; 2014 May; 5(9):2853-63. PubMed ID: 24797310
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.
Lim SC; Choi JE; Kang HS; Han SI
Int J Cancer; 2010 Apr; 126(7):1582-95. PubMed ID: 19728331
[TBL] [Abstract][Full Text] [Related]
19. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production.
Seol HS; Lee SE; Song JS; Lee HY; Park S; Kim I; Singh SR; Chang S; Jang SJ
Cancer Lett; 2016 Nov; 382(2):157-165. PubMed ID: 27612558
[TBL] [Abstract][Full Text] [Related]
20. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
